GENE ONLINE|News &
Opinion
Blog

Spinal Muscular Atrophy
Genentech Unveils Positive Two-Year Data For Spinal Muscular Atrophy Drug
2022-10-13
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
First Oral SMA Drug by Roche Now Available to Newborns
2022-06-01
After FDA Lifts Hold, Novartis to Proceed with Clinical Trials for Expensive Rare Disease Therapy
2021-08-04
Novartis’ Expensive Gene Therapy for SMA Reasserts its Efficacy in Two Clinical Trials
2021-06-24
Jaguar Launches with a Pre-clinical Pipeline of AAV9-Based Gene Therapies
2021-02-28
R&D
Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)
2020-08-17
Genentech Enters Spinal Muscular Atrophy Market with Risdiplam’s FDA Approval
2020-08-11
Spotlight: New Gene Therapies on the Horizon for the Treatment of Neurogenetic Diseases
2020-08-03
Spotlight: Roche’s SMA Drug, Risdiplam Makes Strong Case for Regulatory Approval
2020-07-05
R&D
Biogen’s SMA Drug, Spinraza Continues to Show Benefits in Pre-Symptomatic Patients
2020-06-14
R&D
Weekly Cover: Eisai to Launch “NouKNOWTM” in Japan for Regular Self-assessment of Brain Health
2020-03-26
FDA Okays Expensive Gene Therapy for Infantile-Onset Spinal Muscular Atrophy
2019-05-29
LATEST
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
2024-04-10
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
Scroll to Top